AARTI DRUGS LTD.
P&L
Quarterly Consolidated
vs Q2 FY26
Aarti Drugs Reports 8% YoY Revenue Growth in Q3 FY26, Up 49% PAT YoY in 9M FY26
03 Feb 2026 · 3 Feb, 9:32 pm
Summary
Aarti Drugs Limited, a Mumbai based diversified and fully integrated pharmaceutical company, reported its audited Financial Results for the Quarter and Nine Months ended 31st December 2025. The company's revenue grew by 8% YoY in Q3 FY26, with EBITDA and PAT standing at Rs. 56.3 crore and Rs. 40.5 crore respectively. The 9M FY26 PAT showed a 49% YoY growth.
Key Highlights
- 1
Revenue stood at Rs. 602.9 crore as compared to Rs. 557.1 crore in Q3 FY25, reflecting a growth of 8% YoY
- 2
EBITDA stood at Rs. 56.3 crore versus Rs. 62.3 crore in Q3 FY25, down 10% YoY, with EBITDA margin at 9.3%
- 3
PAT stood at Rs. 40.5 crore as compared to Rs. 25.7 crore in Q3 FY25, up 58% YoY, translating to a PAT margin of 6.7%
- 4
Revenue stood at Rs. 1,846.6 crore as compared to Rs. 1,713.4 crore in 9M FY25, reflecting a growth of 8% YoY
- 5
EBITDA stood at Rs. 215.0 crore versus Rs. 196.9 crore in 9M FY25, up 9% YoY, with EBITDA margin at 11.6%
- 6
PAT stood at Rs. 139.7 crore as compared to Rs. 94.0 crore in 9M FY25, up 49% YoY, translating to a PAT margin of 7.6%
Management Comments
Mr. Adhish Patil
CFO & COO, Aarti Drugs Limited
During the third quarter of FY26, Aarti Drugs delivered a steady performance, supported by healthy traction in the domestic market and strong growth in the export formulations segment... We are confident in our ability to ramp up to 50% by March or April 2026... Our Salicylic Acid plant in Tarapur has hit a significant milestone, scaling to above ~300 tonnes per month recently... The Company remains focused on operational efficiency, margin improvement, and capacity ramp-up, while maintaining compliance with regulatory standards and capital discipline.
Informational and educational content only. Not investment advice.